Abstract 38P
Background
Claudin 18.2 (CLDN18.2) is expressed in normal gastric tissue and gastric cancers. Zolbetuximab is a chimeric IgG1 monoclonal antibody that selectively targets CLDN18.2, inducing antibody- and complement-dependent cytotoxicity and cancer cell lysis. In phase 3 studies of zolbetuximab for HER2-negative, advanced gastric/gastroesophageal junction adenocarcinomas (SPOTLIGHT, GLOW), the most frequent adverse events were nausea and vomiting (N/V). We investigated the mechanism of zolbetuximab-induced N/V and effects of antiemetic agents on gastric injury and emesis frequency in ferrets.
Methods
Ferrets were administered zolbetuximab with/without single or combination antiemetic treatment (Table). Retching/vomiting were monitored for 6 hours, after which gastric tissues were sampled for histopathologic assessment. The study was conducted twice. Table: 38P
Study groups
Antiemetic Agent(s) | |||
Group (n=4, each study) | Emesis Agent | Study 1 | Study 2 |
1 – Normal | Saline IV | --- | |
2 – Control | Zolbetuximab 1 mg/kg IV | --- | |
3 – DEX | DEX 20 mg/kg IV | ||
4 – OND | OND 3 mg/kg IV | ||
5 – FOS | FOS 3 mg/kg IV | ||
6 – OLA | OLA 0.03 mg/kg IM | ||
7 – Combination | DEX+OND+FOS+OLA | OND+FOS |
DEX, dexamethasone; FOS, fosaprepitant; IM, intramuscular; IV, intravenous; OLA, olanzapine; OND, ondansetron.
Results
Zolbetuximab induced emesis within 30 minutes of administration. Singly, dexamethasone (DEX), ondansetron (OND), and fosaprepitant (FOS) significantly reduced emesis vs control (no antiemetic) in Study 1; olanzapine (OLA) did not. In Study 2, FOS alone (but not DEX, OND, or OLA) almost completely suppressed emesis. Further, both combination regimens containing FOS reduced emesis. Histopathologic analysis indicated that zolbetuximab induced gastric injury, evidenced by submucosal inflammation in the corpus and pylorus. DEX alone and the DEX-based combination regimen showed a tendency to alleviate submucosal inflammation in the corpus and pylorus, although the other antiemetics did not show any clear suppression of gastric mucosal damage. The combination of OND+FOS also tended to alleviate gastric mucosal abnormalities.
Conclusions
These findings in ferrets demonstrate that zolbetuximab-induced emesis may be associated with gastric mucosal damage. Further, antiemetics may have the potential to mitigate N/V in patients treated with zolbetuximab.
Clinical trial identification
Editorial acknowledgement
This study is funded by Astellas Pharma, Inc. Medical writing/editorial support was provided by Sandra Westra, PharmD, Pamela Barendt, PhD, and Cheryl Casterline, MA, from Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by the study sponsor.
Legal entity responsible for the study
Astellas Pharma, Inc.
Funding
Astellas Pharma, Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09